Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Sernova Corp. (OTC: SEOVF).

Full DD Report for SEOVF

You must become a subscriber to view this report.


Recent News from (OTC: SEOVF)

Sernova Completes Oversubscribed Private Placement of $2,754,000
LONDON, Ontario, July 23, 2018 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH) announces it has completed a non-brokered private placement of $2.754 million, pursuant to which Sernova issued a total of 11,016,000 special warrants in two closing (July 13, 2018, and July...
Source: GlobeNewswire
Date: July, 23 2018 06:00
Sernova Initiates Patient Screening and Recruitment for its US Clinical Trial for Diabetes
LONDON, Ontario, July 05, 2018 (GLOBE NEWSWIRE) -- Sernova Corp. (“Sernova” or the “Company”) (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH) announces that patient screening and recruitment has begun in its regenerative medicine US clinical trial for diabetic patients with ...
Source: GlobeNewswire
Date: July, 05 2018 06:00
Sernova Announces $2 Million Private Placement Financing
THIS NEWS RELEASE IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. LONDON, Ontario, June 26, 2018 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH) is pleased to announce that the Company has secured a $1 mill...
Source: GlobeNewswire
Date: June, 26 2018 06:00
Sernova Announces University of Chicago Institutional Review Board (IRB) Approval of the FDA-cleared Therapeutic Cell Pouch Clinical Study
LONDON, Ontario, May 14, 2018 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH), announces today it has received University of Chicago Institutional Review Board (IRB) approval to begin a new clinical protocol for the FDA-cleared human clinical trial to investigate the C...
Source: GlobeNewswire
Date: May, 14 2018 06:00
Sernova Announces U.S. Phase I/II Cell Pouch Clinical Trial with Prominent Diabetes Clinical Investigator
LONDON, Ontario, May 08, 2018 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH), announces Dr. Piotr Witkowski, M.D., Ph.D., a leading expert in type 1 diabetes (T1D) and islet transplantation, as the Clinical Trial Principal Investigator for Sernova’s new clinica...
Source: GlobeNewswire
Date: May, 08 2018 06:00
Sernova Announces Results of 2018 Annual General Meeting of Shareholders and New Chief Financial Officer
LONDON, Ontario, May 04, 2018 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH), announced shareholder approval of all management resolutions brought forward at the 2018 Annual General Meeting held in Vancouver, April 25th. In addition, we are pleased to announce Mr. Sea...
Source: GlobeNewswire
Date: May, 04 2018 06:00
Sernova Corp.'s (OTCQB: SEOVF) (TSX.V: SVA) (FSE: PSH) Continuous Glucose Monitoring System Approved to be Utilized in Clinical Trial
Food & Drug Administration grants Sernova Corp. notice of approval to utilize its Continuous Glucose Monitoring System in support of clinical trial of its Cell Pouch Global treatment market for type 1 diabetes on pace to grow to $13.6 billion by 2023 Sernova is a clinical stage comp...
Source: NetworkNewsWire
Date: March, 06 2018 09:30
Sernova Obtains FDA Notice of Allowance for Use of Proprietary Cell Pouch System with Continuous Glucose Monitoring Systems in Clinical Trials for Type 1 Diabetes - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - February 23, 2018) - Sernova Corp. (TSXV: SVA) (OTCQB: SEOVF) (FSE: PSH) a clinical stage company developing regenerative medicine technologies for the treatment of chronic diseases including diabetes and hemophilia, announced that continuous gluc...
Source: Newsfile
Date: February, 23 2018 09:00
Sernova's Cell Pouch Regenerative Medicine Clinical Trial for Patients with Type 1 Diabetes Supported with Continuous Glucose Monitoring Systems
LONDON, Ontario, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH), a clinical stage company developing regenerative medicine technologies for the treatment of chronic diseases including diabetes and hemophilia, is pleased to announce continuous glucose mon...
Source: GlobeNewswire
Date: February, 22 2018 06:00
Sernova to Participate at the Biotech Showcase 2018 Healthcare Partnering Conference
LONDON, Ontario, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Sernova Corp (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH), a clinical stage regenerative medicine company, today announced that Dr. Philip Toleikis, Sernova’s President and CEO, will be participating at the 10th annual Biotech Showcase Confer...
Source: GlobeNewswire
Date: January, 05 2018 09:40

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-12N/A0.16N/AN/A0
2018-12-11N/A0.16N/AN/A0
2018-12-100.160.160.160.1616,000
2018-12-070.15980.160.160.156588,767
2018-12-06N/A0.175N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-076,1508,76770.1494Short
2018-11-2920,00039,00051.2821Short
2018-11-2830,000119,60025.0836Cover
2018-11-23350350100.0000Short
2018-11-2120,00043,00046.5116Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SEOVF.


About Sernova Corp. (OTC: SEOVF)

Logo for Sernova Corp. (OTC: SEOVF)

Sernova Corp. is a clinical stage regenerative medicine company developing cell therapy based medical technologies for the treatment of chronic debilitating diseases such as diabetes, blood disorders including hemophilia and other diseases all of which are treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch TM , a scalable, implantable medical device which forms a vascularized organ like environment for the transplantation of its locally immune protected therapeutic cells self cells, donor cells, ethically sourced stem cell derived therapeutic cells or xenogeneic cells which then release proteins and/or hormones as required by the body. The objective of the company s products is to disrupt the standard of care treatments for these serious diseases to improve efficacy, significantly improve patient quality of life and to decrease the severe debilitating disease effects that progress with the standard of care treatments. The product to treat diabetes involves implantation of a small biocompatible medical device under the skin into which are placed immune protected cells which connect to the blood vessel supply to read blood sugar levels and release insulin accordingly, replacing the metabolic function of the pancreas. For hemophelia the cells would release the required protein, Factor VIII on a constant basis reducing or eliminating the need for frequent infusions of Factor VIII.

 

Contact Information

 

 

Current Management

  • Philip M. Toleikis / CEO
  • Scott Langille / CFO
  • Frank Alfred Holler / Chairman
  • Jeffrey Bacha /
  • James Parsons /
  • Philip M. Toleikis /
  • Bruce Allen Weber /

Current Share Structure

  • Market Cap: $44,736,422 - 03/16/2018
  • Issue and Outstanding: 159,374,498 - 10/31/2017
  • Float: 153,570,026 - 10/31/2017

 


Recent Filings from (OTC: SEOVF)

OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: January, 29 2018
Management Discussion and Analysis - SERNOVA CORP. MANAGEMENTS DISCUSSION AND ANALYSIS FOR THE YEARS ENDED OCTOBER 31, 2017 AND 2016
Filing Type: Management Discussion and Analysis - SERNOVA CORP. MANAGEMENTS DISCUSSION AND ANALYSIS FOR THE YEARSFiling Source: OTC Markets
Filing Date: January, 29 2018
Annual Report - SERNOVA CORP. CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED OCTOBER 31, 2017 AND 2016
Filing Type: Annual Report - SERNOVA CORP. CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED OCTOBER 31, 201Filing Source: OTC Markets
Filing Date: January, 29 2018
Quarterly Report - Mangement's Discussion & Analysis For Three & Nine Months Ended July 31, 2017 & 2016
Filing Type: Quarterly Report - Mangement's Discussion & Analysis For Three & Nine Months Ended July 31, Filing Source: OTC Markets
Filing Date: October, 01 2017
Quarterly Report - Sernova Financial Statements July 31, 2017 & 2016
Filing Type: Quarterly Report - Sernova Financial Statements July 31, 2017 & 2016Filing Source: OTC Markets
Filing Date: October, 01 2017

 

 


Daily Technical Chart for (OTC: SEOVF)

Daily Technical Chart for (OTC: SEOVF)


Stay tuned for daily updates and more on (OTC: SEOVF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: SEOVF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SEOVF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SEOVF and does not buy, sell, or trade any shares of SEOVF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/